Haixi Pharma's stock surged 9.54% during intraday trading, showing significant upward momentum in the market session.

The company recently announced the adoption of an H-share incentive plan aimed at establishing a long-term incentive mechanism to align the interests of shareholders, the company, and employees. This announcement, combined with a technical recovery from oversold conditions after the stock had experienced a substantial decline from its historical high, is driving the current rebound.

Fundamentally, Haixi Pharma has reported strong financial performance with revenue increasing 24.79% year-over-year and net profit rising 30.09% for the fiscal year. The company maintains a portfolio of 15 approved generic drugs and is advancing its innovative pipeline, including a drug approaching Phase III clinical trials, contributing to positive investor sentiment.